Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million

The Director disposed of 14,180 shares for ~$2.3 million on August 4, 2026.

The transaction involved an 83% reduction in Clark's indirect equity holdings, including shares acquired via option exercise.

The disposal was executed through The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account.

The activity occurred as the stock recorded a one-year return of 262% as of the August 4, 2026 transaction date.

Ian T. Clark, a Director at Guardant Health, Inc. (NASDAQ:GH) , reported a sale of 14,180 shares of common stock on Aug. 4, 2026, according to a recent SEC Form 4 filing .

Transaction value based on SEC Form 4 weighted average sale price ($158.92); post-transaction value based on Aug. 4, 2026 market close ($159.79).

Guardant Health is a precision oncology company with a market capitalization of $21.4 billion, generating $1.2 billion in TTM revenue through its portfolio of liquid biopsy diagnostic tests. The company leverages advanced molecular analytics and comprehensive genomic profiling to establish a competitive moat in the high-growth oncology diagnostics market, though it remains in a net loss position as it scales operations and invests in research and development initiatives.

Investors should treat insider transactions with some nuance. After all, insiders sell shares for a variety of reasons, ranging from tax purposes to estate planning. In any event, outside investors should consider a company’s fundamentals before deciding to buy or sell shares. With that in mind, let’s take a closer look at Guardant Health.